Expert Opinion on Therapeutic Patents

Papers
(The TQCC of Expert Opinion on Therapeutic Patents is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)
ArticleCitations
Recent developments of agents targeting Vibrio cholerae : patents and literature data46
Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)42
Malaria transmission blocking compounds: a patent review40
Update on mGlu4 modulator patents: 2017 to present37
RORγt inhibitors in clinical development for the treatment of autoimmune diseases: challenges and opportunities36
Traf2- and Nck-interacting kinase inhibitors: a patent review (2008–2024)35
The role of patent analysis in target selection34
FAK inhibitors in cancer, a patent review – an update on progress30
Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present)29
Synthetic methodologies and PET imaging applications of fluorine-18 radiotracers: a patent review29
Caspase inhibitors: a review on recently patented compounds (2016–2023)28
P2X receptor antagonists and their potential as therapeutics: a patent review (2010–2021)28
A patenting perspective of fat mass and obesity associated protein (FTO) inhibitors: 2017–present27
P2Y 12 R antagonists in antithrombotic therapy: a patent and literature review (2019–present)26
Current trends of benzothiazoles in drug discovery: a patent review (2015–2020)23
A patent review of hepatitis B virus core protein allosteric modulators (2019-present)23
An updated patent review of AKT inhibitors (2020 – present)23
The intriguing role of USP30 inhibitors as deubiquitinating enzymes from the patent literature since 201322
Patent review of cannabinoid receptor type 2 (CB 2 R) modulators (2016-present)22
Inhibition of GTPase KRAS G12D : a review of patent literature22
A patent review of MAPK inhibitors (2018 – present)22
PDE1 inhibitors: a review of the recent patent literature (2008-present)21
Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia – a patent review21
GPR120 agonists for the treatment of type 2 diabetes: an updated patent review (2020-present)20
Antiprotozoal drugs: challenges and opportunities20
Targeting the LPA1 signaling pathway for fibrosis therapy: a patent review (2010-present)19
Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors – a review of patent literature from 2019–June 202319
Insights and trends in development of TEAD–YAP/TAZ inhibitors: a review of PCT patents (2022 to June 2025)19
Small-molecule RNA ligands: a patent review (2018–2024)16
Recent advances in the development of P2Y 14 R inhibitors: a patent and literature review (2018-present)16
A patent review of P2X7 receptor antagonists to treat inflammatory diseases (2018–present)16
Therapeutic compounds targeting interleukin-1 receptor-associated kinase 4 (IRAK4): an updated patent review (2019 to present)16
An updated patent review of MALT1 inhibitors (2021–present)16
Phosphodiesterase 2 (PDE2) inhibitors: an updated patent review (2017–present)16
A patent review of IDH1 inhibitors (2018-present)16
The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders16
A patent and literature review of CDK12 inhibitors15
An updated patent review on PD-1/PD-L1 antagonists (2022-present)15
Biofilm and bacterial membrane vesicles: recent advances15
Dopamine D3 receptor ligands: a patent review (2014–2020)15
The challenging inhibition of Aldose Reductase for the treatment of diabetic complications: a 2019–2023 update of the patent literature15
Antimalarial drugs: what’s new in the patents?15
Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020–present)15
Part-II: an update of Schiff bases synthesis and applications in medicinal chemistry-a patent review (2016-2023)14
Drugs and nanoformulations for the management of Leishmania infection: a patent and literature review (2015-2022)13
Small molecules targeting immune checkpoint proteins for cancer immunotherapy: a patent and literature review (2020–2024)13
Are patents important indicators of innovation for Chagas disease treatment?13
Sirtuin modulators: a review of patents from 2020 to 202413
A patent review of NLRP3 inhibitors to treat autoimmune diseases12
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) in cancer: a patent review12
An updated patent review on drugs for the treatment of tuberculosis (2018-present)12
Trends in covalent drug discovery: a 2020–23 patent landscape analysis focused on select covalent reacting groups (CRGs) found in FDA-approved drugs12
An updated patent review of EZH2 inhibitors (2024–present)12
The management ofBabesia, amoeba and other zoonotic diseases provoked by protozoa11
A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019–present)11
Correction11
An updated patent review of GPR40/ FFAR1 modulators (2020 – present)11
Implementation and outcomes of China’s drug patent linkage system: lessons from international experience11
Biomedical applications of prokaryotic carbonic anhydrases: an update11
Progress with polo-like kinase (PLK) inhibitors: a patent review (2018–present)11
An updated patent review on rational combinations of HDAC inhibitors for cancer chemotherapy (2020 – present): part 1-patent granted11
The patent review of the biological activity of tropane containing compounds11
An updated patent review of TRPA1 antagonists (2020 – present)11
Targeting glucose metabolism to develop anticancer treatments and therapeutic patents11
0.084408044815063